TY - JOUR
T1 - Effectiveness of interferon alfa-2a combined with phototherapy for mycosis fungoides and the Sézary syndrome
AU - Kuzel, Timothy M.
AU - Roenigk, Henry H.
AU - Samuelson, Ellen
AU - Herrmann, James J.
AU - Hurria, Arti
AU - Rademaker, Alfred W.
AU - Rosen, Steven T.
PY - 1995/1/1
Y1 - 1995/1/1
N2 - Purpose: To investigate the efficacy of combined topical therapy and systemic interferon alfa-2a in patients with mycosis fungoides (MF) and the Sézary syndrome (SS). Patients and Methods: Between December 1987 and April 1993, 39 patients with all stages of MF and SS were treated with combined phototherapy and systemic interferon alfa-2a as part of two institutional studies. The initial phase I study of 15 patients established the maximum-tolerated dose of interferon and has been previously reported. Subsequently, 24 patients have been entered onto a phase II trial. Long-term follow-up data are provided for both studies. Results: The median follow-up duration for the entire cohort is 28 months. Patients with all stages of disease were enrolled (stage IB, n = 14; IIA, n = 5; IIB, n = 6; III, n = 8; IVA, n = 5; IVB, n = 1). Thirty-four patients had received previous therapy. Overall, 36 of 39 patients achieved a complete response (CR; 62%) or partial response (28%) to therapy. The median response duration is 28 months (range, 1 to 64). Twenty-nine of 39 patients are alive, with a median survival duration of 62 months (range, 1 to 66). Conclusion: Interferon alfa-2a combined with phototherapy is an effective, safe, durable therapy for MF and SS.
AB - Purpose: To investigate the efficacy of combined topical therapy and systemic interferon alfa-2a in patients with mycosis fungoides (MF) and the Sézary syndrome (SS). Patients and Methods: Between December 1987 and April 1993, 39 patients with all stages of MF and SS were treated with combined phototherapy and systemic interferon alfa-2a as part of two institutional studies. The initial phase I study of 15 patients established the maximum-tolerated dose of interferon and has been previously reported. Subsequently, 24 patients have been entered onto a phase II trial. Long-term follow-up data are provided for both studies. Results: The median follow-up duration for the entire cohort is 28 months. Patients with all stages of disease were enrolled (stage IB, n = 14; IIA, n = 5; IIB, n = 6; III, n = 8; IVA, n = 5; IVB, n = 1). Thirty-four patients had received previous therapy. Overall, 36 of 39 patients achieved a complete response (CR; 62%) or partial response (28%) to therapy. The median response duration is 28 months (range, 1 to 64). Twenty-nine of 39 patients are alive, with a median survival duration of 62 months (range, 1 to 66). Conclusion: Interferon alfa-2a combined with phototherapy is an effective, safe, durable therapy for MF and SS.
UR - http://www.scopus.com/inward/record.url?scp=0028896192&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028896192&partnerID=8YFLogxK
U2 - 10.1200/JCO.1995.13.1.257
DO - 10.1200/JCO.1995.13.1.257
M3 - Article
C2 - 7799028
AN - SCOPUS:0028896192
VL - 13
SP - 257
EP - 263
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
SN - 0732-183X
IS - 1
ER -